About Ritlecitinib API
Therapeutic CategoryAnti-Cancer/ Oncology-pt
CAS Number
1792180-81-4
API Technology
Synthetic
Dose Form
Cream
Dr Reddy's Development Status
Under Development
Mechanism of Action
Ritlecitinib irreversibly inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family by blocking the adenosine triphosphate (ATP) binding site. In cellular settings, ritlecitinib inhibits cytokine induced STAT phosphorylation mediated by JAK3-dependent receptors. Additionally, ritlecitinib inhibits signaling of immune receptors dependent on TEC kinase family members. The relevance of inhibition of specific JAK or TEC family enzymes to therapeutic effectiveness is not currently known.
Indication
Litfulo is specifically indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.
Related APIs
Enzalutamide-pt
Anti-Cancer/ Oncology-pt
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!